ERBB2 and breast carcinoma: Although the majority of trials towards bsAbs focus on HER2-positive breast cancer, preclinical studies in TNBC showed promising immunomodulatory effects of BiTEs targeting TROP-2 resulting in reduced tumor growth [61].